Synfine Drugs Profile
Key Indicators
- Authorised Capital ₹ 11.00 Cr
as on 13-12-2024
- Paid Up Capital ₹ 4.87 Cr
as on 13-12-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.51 Cr
as on 13-12-2024
- Revenue 12.49%
(FY 2023)
- Profit 2472.93%
(FY 2023)
- Ebitda 57.31%
(FY 2023)
- Net Worth 29.72%
(FY 2023)
- Total Assets -18.77%
(FY 2023)
About Synfine Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 11.00 Cr and a paid-up capital of Rs 4.87 Cr.
The company currently has active open charges totaling ₹9.51 Cr.
Saida Battu and Chandra Battu serve as directors at the Company.
- CIN/LLPIN
U24304TG2017PTC116006
- Company No.
116006
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Mar 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Synfine Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saida Battu  | Managing Director | 20-Mar-2017 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chandra Battu | Director | 20-Mar-2017 | Current |
Financial Performance of Synfine Drugs.
Synfine Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.49% increase. The company also saw a substantial improvement in profitability, with a 2472.93% increase in profit. The company's net worth Soared by an impressive increase of 29.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synfine Drugs?
In 2023, Synfine Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Syn - Finechem Laboratories Private LimitedActive 21 years 4 monthsSaida Battu and Chandra Battu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 04 Sep 2019 | ₹9.51 Cr | Open |
How Many Employees Work at Synfine Drugs?
Synfine Drugs has a workforce of 21 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synfine Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synfine Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
